Novo Nordisk bears would be quick to point a paw at the company's so far sole competitor in the GLP-1 race, Eli Lilly. ... VA., by brothers David and Tom Gardner, ...

Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from ...

Novo said on Friday its current CEO will step down The obesity drug maker has struggled to compete against U.S. rival Eli Lilly American CEO may be better to deal with a Trump admin, analysts said ...

Jørgensen was well aware that Novo Nordisk would need to push an aggressive pace of drug development to stay ahead. In late 2023, the company announced that it would buy a startup developing ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...